Stay updated with breaking news from Nasdaq Cbay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com lowered shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) from a hold rating to a sell rating in a research report released on Monday morning. CBAY has been the subject of a number of other research reports. Oppenheimer raised their price target on shares of CymaBay Therapeutics from $10.00 to $12.00 and gave the […]
CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price target boosted by equities research analysts at BTIG Research from $15.00 to $18.00 in a note issued to investors on Tuesday, The Fly reports. BTIG Research’s target price indicates a potential upside of 53.85% from the stock’s previous close. CBAY has been the subject of several […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) insider Charles Mcwherter sold 21,749 shares of the business’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $8.16, for a total transaction of $177,471.84. Following the completion of the sale, the insider now directly owns 15,000 shares of the […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) insider Charles Mcwherter sold 21,749 shares of the business’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $8.16, for a total transaction of $177,471.84. Following the completion of the transaction, the insider now directly owns 15,000 shares of the […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) saw a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 10,130,000 shares, a decrease of 8.5% from the April 30th total of 11,070,000 shares. Based on an average trading volume of 1,700,000 shares, the short-interest ratio is […]